A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in Children and Adolescents with Newly Diagnosed Type 1 Diabetes (T1D)
This Study is
No Longer Enrolling
Details
Age
Child
Type of Study
Treatment
Locations
Barbara Davis Center
Outpatient CTRC
UCD Barbara Davis Center
University of Colorado Hospital
Study ID
Protocol Number: 19-0489
More information available at ClinicalTrials.gov: NCT03875729
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers